GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alto Neuroscience Inc.
The stock of Alto Neuroscience, a biotech company using AI to develop psychiatric drugs, reflects the potential of its innovative approach. The price is a bet on the success of its clinical programs and the ability to personalize depression treatment.
Share prices of companies in the market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using AI and EEG data to develop precision treatments for mental disorders such as depression. We classify it as a "psychedelic pharmaceutical" (broadly defined). The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Alto Neuroscience is a biotech company that uses biomarker analysis and artificial intelligence to develop personalized medications for mental disorders. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Alto's performance.
Change in the price of a company, segment, and market as a whole per day
ANRO - Daily change in the company's share price Alto Neuroscience Inc.
The daily fluctuations of Alto Neuroscience, a mental health company, reflect the high volatility inherent in biotech. This metric measures sensitivity to clinical trial data and regulatory announcements, serving as a key element in the risk assessment formulas of System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Alto Neuroscience, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ANRO's performance, which focuses on mental health, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Alto Neuroscience uses brain biology data to develop personalized psychiatric medications. It's a cutting-edge biotech company, and its shares are driven by research news. Their high volatility reflects the high risks and promises of treating mental disorders.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alto Neuroscience Inc.
For Alto Neuroscience, Inc., the year-over-year performance is a story of precision medicine in psychiatry. Its 12-month market capitalization depends entirely on clinical trial data from its drugs, which are selected for patients based on biomarkers. Success could lead to breakthroughs in the treatment of depression and other disorders.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Alto Neuroscience, a recent IPO, uses biomarkers and AI to develop drugs for mental disorders. The chart shows how the market views its innovative, data-driven approach to this complex area of medicine compared to the traditional biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alto Neuroscience is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its psychiatric drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alto Neuroscience Inc.
Alto Neuroscience is a biotech company developing biomarker-based psychiatric drugs. Its monthly performance is driven by progress in its clinical trials. News about research results and validation of its approach to personalized medicine are its primary drivers.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Alto Neuroscience is a clinical-stage biotech company that uses biomarkers and AI to develop personalized medications for mental disorders such as depression. The graph below illustrates the dynamics of the biotech sector, where precision psychiatry is a new and promising approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alto Neuroscience is a biotech company developing personalized treatments for mental disorders. Its shares thrive on clinical trials and scientific discoveries. The success or failure of its research drives sharp price movements unrelated to overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alto Neuroscience Inc.
Alto Neuroscience's weekly performance reflects the search for personalized treatments for mental illnesses. This biotech company's stock price is responding to data from clinical trials that use biomarkers to select the right medication for each patient.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Alto Neuroscience develops personalized medications for the treatment of mental disorders using biomarkers. This is a cutting-edge approach in psychiatry. The chart will show whether Alto's share price fluctuations are driven by its unique scientific data or reflect general investor sentiment toward the complex neuroscience sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alto Neuroscience is a biotech company. Its shares can be highly volatile and react to research news. This chart will help you understand whether Alto Neuroscience is living in its own world of clinical trials, or whether the overall market environment is influencing its stock price.
Market capitalization of the company, segment and market as a whole
ANRO - Market capitalization of the company Alto Neuroscience Inc.
Alto Neuroscience's market capitalization chart tells the story of a biotech company using biomarkers and AI to develop personalized psychiatric medications. Its performance since its recent IPO reflects the market's appreciation of its innovative approach to treating depression and other disorders. Its trajectory is a bet on psychiatry becoming a more precise science.
ANRO - Share of the company's market capitalization Alto Neuroscience Inc. within the market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using biomarker-based precision psychiatry to develop drugs for central nervous system disorders. Its market cap reflects the potential of this innovative approach. The chart shows how much the market is betting on its ability to find the right drug for the right patient.
Market capitalization of the market segment - Pharma psycho
Alto Neuroscience is a biotech company that uses EEG data and other biomarkers to develop personalized medications for psychiatry. The chart below shows the market capitalization of this complex sector. Its dynamics reflect the hope that precision medicine may finally offer a breakthrough in the treatment of depression and other disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alto Neuroscience is a biotech company using brain data to develop personalized medications for psychiatry. Its market cap is a bet on revolutionizing the treatment of mental disorders. Its growth reflects hopes that precision medicine will also reach this complex field.
Book value capitalization of the company, segment and market as a whole
ANRO - Book value capitalization of the company Alto Neuroscience Inc.
Alto Neuroscience's balance sheet is its capital and AI-powered platform for precise diagnostics and the development of personalized medications for mental disorders. This is the tangible, scientific foundation for a new era in psychiatry. How is this innovative biotech asset shaping up? The chart below shows its dynamics.
ANRO - Share of the company's book capitalization Alto Neuroscience Inc. within the market segment - Pharma psycho
Alto Neuroscience develops biomarker-based psychiatric drugs, which requires advanced laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its personalized treatment approach.
Market segment balance sheet capitalization - Pharma psycho
Alto Neuroscience develops psychiatric drugs using a precision medicine approach. Its business is driven by science and data. The book value chart shows how "light" the company's capital base is at the forefront of neuroscience.
Book value of all companies included in the broad market index - GURU.Markets
Alto Neuroscience develops personalized medications for the treatment of mental disorders. Its book value is derived from its AI- and biomarker-based platform, as well as its clinical trial capital. The chart shows the material foundation on which this new approach to psychiatry is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alto Neuroscience Inc.
Alto Neuroscience's balance sheet is capital. But the market sees it as a pioneer in personalized psychiatry. The chart shows the "hope factor": the premium for its AI-powered platform, which could change the way depression and other disorders are treated.
Market to book capitalization ratio in a market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using precision psychiatry to develop drugs for mental disorders. This chart shows how much investors believe in its innovative, data-driven approach to treating depression and other conditions.
Market to book capitalization ratio for the market as a whole
Alto Neuroscience is a biotech company that uses EEG data and other biomarkers to develop personalized medications for mental disorders. Its approach is "precision psychiatry." This chart shows the overall valuation, but how does the market value a company trying to make treatment for depression and schizophrenia more scientific and personalized?
Debts of the company, segment and market as a whole
ANRO - Company debts Alto Neuroscience Inc.
Alto Neuroscience takes a unique approach to psychiatric drug development. This chart shows how the company funds its expensive strategy, which includes conducting clinical trials to validate the effectiveness of its biomarker- and AI-based approaches.
Market segment debts - Pharma psycho
Alto Neuroscience develops drugs for personalized psychiatry, using biomarkers to tailor treatment. This is a cutting-edge but complex approach. This chart shows how the company is funding its innovative clinical trials, aiming to change the paradigm of mental health treatment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alto Neuroscience Inc.
Alto Neuroscience is a biopharmaceutical company using precision psychiatry methods to develop drugs. This chart shows how it funds its innovative but expensive approach to research. Debt here represents an investment in a new paradigm for treating mental disorders, which carries high scientific and financial risks.
Market segment debt to market segment book capitalization - Pharma psycho
Alto Neuroscience develops precision psychiatric drugs using biomarkers to tailor therapy. This chart shows the leverage in the cutting-edge psychopharmacology sector. It helps understand how companies finance their innovative but risky clinical trials and how Alto manages its capital.
Debt to book value of all companies in the market
Alto Neuroscience develops psychiatric drugs using biomarkers for personalized treatment. It's a cutting-edge biotech company backed by venture capital. Its overall market debt is irrelevant to its business model, which is betting on scientific breakthroughs in one of the most complex areas of medicine.
P/E of the company, segment and market as a whole
P/E - Alto Neuroscience Inc.
This metric for Alto Neuroscience, a company developing biomarker-based psychiatric drugs, demonstrates the company's scientific approach. The multiple reflects investors' belief that its personalized medicine methods will lead to more effective treatments for depression and other disorders.
P/E of the market segment - Pharma psycho
Alto Neuroscience's focus on treating mental disorders is personalized medicine. This chart shows the average score for biopharmaceutical companies. It helps to understand that Alto, with its biomarker-based approach, is being evaluated based on its potential to make depression treatment more precise and effective.
P/E of the market as a whole
Alto Neuroscience, Inc. is a biopharmaceutical company using biomarkers and AI to develop personalized treatments for mental illnesses such as depression. This cutting-edge scientific approach is key. This overall risk appetite chart is an indicator of how willing investors are to fund this innovative but complex field of medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alto Neuroscience Inc.
Alto Neuroscience is a clinical-stage biotech company using biomarkers to develop personalized medications for mental disorders. This chart reflects expectations for its innovative approach. The trend represents the market's assessment of the likelihood of success for its clinical programs.
%20P%2FE%20Alto%20Neuroscience%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alto-Neuroscience-Inc.&v=1772681291947 "Chart of the company's future (projected) P/E Alto Neuroscience Inc.")
Future (projected) P/E of the market segment - Pharma psycho
Alto Neuroscience is a biotech company using biomarkers and AI to develop personalized medications for mental disorders. This chart shows profitability expectations for the sector, helping to understand how highly the market values its innovative approach to psychiatry, one of the most complex areas of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772681291977 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Alto Neuroscience, Inc. is a biopharmaceutical company using EEG data and biomarkers to develop personalized medications for mental disorders. This chart shows investors' risk appetite. For a company with an innovative approach to psychiatry, it reflects the market's confidence in the potential of precision medicine in this complex field.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681292019 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alto Neuroscience Inc.
Alto Neuroscience, Inc. is a biopharmaceutical company using a precision medicine approach to developing drugs for mental disorders. Its financial performance, as shown in this chart, is comprised of clinical trial expenses. It illustrates the cost of developing a new generation of biomarker-based mental health drugs.
Profit of companies in the market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using precision medicine to develop drugs for mental disorders. The company uses biomarkers to identify patients most likely to benefit from a drug. This graph illustrates how a personalized approach can improve the odds of success and transform profitability in the complex field of psychiatry.
Overall market profit
Alto Neuroscience is a biotech company using EEG data and biomarkers to develop personalized medications for the treatment of mental disorders. This is a cutting-edge approach in psychiatry. The company's success depends on scientific breakthroughs. This overall market return chart provides the backdrop against which investors decide whether they are willing to fund such complex scientific projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alto Neuroscience Inc.
Alto Neuroscience is a biopharmaceutical company using AI and biomarkers to develop personalized medications for mental disorders. The profit/loss projection in this chart is a bet on the success of its high-tech approach to psychiatry.
%20profit%20of%20the%20company%20Alto%20Neuroscience%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alto-Neuroscience-Inc.&v=1772681292169 "Graph of future (projected) profit of the company Alto Neuroscience Inc.")
Future (predicted) profit of companies in the market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using biomarkers and AI to develop personalized medications for mental disorders such as depression. This chart shows the revenue forecast for the psychopharmaceutical sector, allowing us to assess how Alto's breakthrough approach could change the treatment paradigm in psychiatry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772681292179 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Alto Neuroscience is a biopharmaceutical company using precision medicine to treat mental disorders. Its success depends on clinical trials. This graph, reflecting market sentiment, affects the availability of capital to fund innovative but risky approaches in pharmaceuticals.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681292194 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alto Neuroscience Inc.
Alto Neuroscience is a biopharmaceutical company using biomarkers and AI to develop personalized medications for mental disorders. This chart reflects investor expectations for its innovative approach. The valuation is a bet on a breakthrough in precision psychiatry.
P/S market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using a precision medicine approach to develop drugs for mental disorders. It analyzes patients' biomarkers to select the most effective treatments. This chart reflects investor expectations for this innovative approach, showing how the market perceives the company's potential to transform the treatment of depression and other disorders.
P/S of the market as a whole
Alto Neuroscience is a clinical-stage biopharmaceutical company using precision psychiatry to develop personalized medications for depression and other disorders. This chart helps understand how the market is evaluating innovative, yet risky, biomarker-based approaches to treating mental illness.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alto Neuroscience Inc.
Alto Neuroscience develops personalized psychiatry drugs using biomarkers to tailor treatments. This chart shows its valuation relative to projected future sales. It reflects investor expectations for a breakthrough in mental health treatment thanks to its scientific approach.
%20P%2FS%20Alto%20Neuroscience%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alto-Neuroscience-Inc.&v=1772681292320 "The graph of the company's future (projected) P/S Alto Neuroscience Inc.")
Future (projected) P/S of the market segment - Pharma psycho
Alto Neuroscience is a clinical-stage biopharmaceutical company using a precision psychiatry approach to develop targeted drugs for the treatment of central nervous system disorders, such as depression. This chart reflects investor expectations for its innovative scientific platform and potential future revenue.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772681292336 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Alto Neuroscience is a biopharmaceutical company using precision medicine to develop drugs for the treatment of mental disorders. Its future depends on the success of clinical trials. This general expectations chart for ANRO is not a direct driver. The company operates in an area with a huge unmet need, independent of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681292401 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alto Neuroscience Inc.
This chart illustrates the financial trajectory of a biotech company. For Alto Neuroscience, which uses AI and biomarkers to develop personalized psychiatric drugs, it reflects the funds raised from investors to fund clinical trials.
Sales of companies in the market segment - Pharma psycho
Alto Neuroscience is a clinical-stage biopharmaceutical company using biomarkers to develop personalized medications for mental disorders. This chart shows revenue in the pharmaceutical sector. Alto's approach has the potential to revolutionize psychiatry, making treatment more targeted and effective.
Overall market sales
Alto Neuroscience is a biotech company that uses EEG data and biomarkers to develop personalized medications for mental disorders. This is at the forefront of psychiatry. The success of its approach reflects how big data and AI are transforming drug development, making medicine more precise and effective.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alto Neuroscience Inc.
Alto Neuroscience develops drugs for personalized treatment of mental disorders, using biomarkers to tailor therapy. Future sales projections depend on the success of this innovative approach in psychiatry.
%20sales%20of%20the%20company%20Alto%20Neuroscience%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alto-Neuroscience-Inc.&v=1772681292443 "Schedule of future (projected) sales of the company Alto Neuroscience Inc.")
Future (projected) sales of companies in the market segment - Pharma psycho
Alto Neuroscience, Inc. uses a precision medicine approach to develop drugs for mental disorders. The forecast for the psychopharmaceutical sector highlights the search for new solutions. The graph reflects the significant demand for innovative approaches that can tailor treatments individually based on patient biomarkers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772681292454 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Alto Neuroscience is a biopharmaceutical company developing drugs for precision psychiatry. Its success depends on the results of clinical trials. The need for effective treatments for mental disorders is enormous and is not dependent on economic cycles. This graph is important only in terms of the overall investment climate for the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681292476 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alto Neuroscience Inc.
Alto Neuroscience is a biopharmaceutical company using precision medicine to develop treatments for mental disorders. Being in the clinical trials stage, it incurs high R&D expenses. This chart shows the "cost of innovation"—the amount of investment in developing a new approach to treating brain disorders.
Market segment marginality - Pharma psycho
Alto Neuroscience is a biotech company using biomarkers and AI to develop personalized medications for mental disorders. Its profitability depends on the success of this cutting-edge approach. This metric reflects the structure of its research investments compared to other companies working in the field of psychopharmacology.
Market marginality as a whole
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company developing personalized treatments for mental disorders using biomarkers. This chart reflects average revenue. Compared to this, Alto is a bet on the future of psychiatry. The company is not profitable and is investing in science that could change the way treatment is conducted.
Employees in the company, segment and market as a whole
Number of employees in the company Alto Neuroscience Inc.
Alto Neuroscience is a biopharmaceutical company using precision medicine to develop treatments for mental disorders. Its team of scientists and clinicians is its greatest asset. The growth in this chart is directly related to the progress of its platform and the expansion of clinical trials for its personalized treatment approaches.
Share of the company's employees Alto Neuroscience Inc. within the market segment - Pharma psycho
Alto Neuroscience is a biopharmaceutical company using AI and biomarker data to develop personalized medications for mental disorders. This chart highlights its scientific leadership. It reflects the percentage of neuroscientists, psychiatrists, and data scientists working at the intersection of psychiatry and AI that Alto is attracting for its breakthrough approach.
Number of employees in the market segment - Pharma psycho
Alto Neuroscience uses EEG data and biomarkers to develop personalized psychiatric medications. This graph illustrates a breakthrough approach to treating mental disorders. The growth of the research team here reflects the hope of moving beyond trial and error to precision medicine, where treatment is tailored to each patient.
Number of employees in the market as a whole
Alto Neuroscience, Inc. uses data to develop personalized psychiatric medications. This is a cutting-edge scientific field. Their development is independent of the overall economic situation, as this chart illustrates. Success in clinical trials and the ability to prove the effectiveness of their approach determine their future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alto Neuroscience Inc. (ANRO)
Alto Neuroscience is a biopharmaceutical company using AI and biomarkers to develop personalized medications for mental disorders. It's at the cutting edge of psychiatry. This chart shows how the market values precision medicine. The astronomical market cap per employee reflects the potential of their platform to revolutionize depression treatment.
%20of%20the%20company%20Alto%20Neuroscience%20Inc.%20(ANRO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alto-Neuroscience-Inc.-ANRO&v=1772681292630 "Chart of market capitalization per employee (in thousands of dollars) of the company Alto Neuroscience Inc. (ANRO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Alto Neuroscience uses biological markers to develop personalized psychiatric medications. This is a cutting-edge approach in pharmaceuticals. This chart shows the high market premium for this innovative platform. The high employee valuation reflects the company's team's belief that it can revolutionize the treatment of depression and other disorders.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772681292652 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Alto Neuroscience is a biopharmaceutical company using biomarkers to develop personalized medications for mental disorders. This chart reflects the employee's high rating, as their innovative approach has the potential to dramatically improve the effectiveness of psychiatric treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681292708 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alto Neuroscience Inc. (ANRO)
Alto Neuroscience is a biotech company developing "precision psychiatry." They use biomarkers (EEG, genetics) to select the right medication for depression or schizophrenia for each individual patient. This is R&D. This negative metric shows how much the company spends on each scientist and doctor to test this innovative approach in clinical trials.
%20Chart%20Alto%20Neuroscience%20Inc.%20(ANRO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alto-Neuroscience-Inc.-ANRO&v=1772681292765 "Company Profit Per Employee (in thousands of dollars) Chart Alto Neuroscience Inc. (ANRO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Alto Neuroscience (ANRO) is a biotech company using AI and biomarkers to develop psychiatric drugs. For a clinical-stage company, this graph is a theoretical benchmark. All of ANRO's current operations are unprofitable. Success would mean that their innovative approach to R&D has resulted in a drug that will generate profits above industry standards.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772681292779 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Alto Neuroscience (ANRO) is a biotech company using AI and biomarkers to develop psychiatric drugs. It is a clinical-stage R&D company. Negative profit per employee reflects the investment in the research team. The graph shows the "cost" of trying to create a new generation of antidepressants.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681292815 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alto Neuroscience Inc. (ANRO)
Alto Neuroscience is a biotech company using AI to develop personalized medications for psychiatry. This chart reflects its status as an R&D company. Lack of revenue is normal. In the future, this metric will become a measure of the commercial success of its innovative approach to treating mental disorders.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alto-Neuroscience-Inc.-ANRO&v=1772681292874 "Sales chart per company employee Alto Neuroscience Inc. (ANRO)")
Sales per employee in the market segment - Pharma psycho
Alto Neuroscience is a biotech company using AI and biomarkers to develop personalized medications for mental disorders (e.g., depression). During the R&D phase, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) by advancing their innovative approach.
Sales per employee for the market as a whole
Alto Neuroscience is a clinical-stage biotech company using AI and biomarkers to develop personalized medications for mental disorders. It's an R&D company. This chart shows revenue per employee. Predictably, it's zero. It emphasizes that the company doesn't sell products but rather invests in science.
Short shares by company, segment and market as a whole
Shares shorted by company Alto Neuroscience Inc. (ANRO)
Alto Neuroscience is a biotech company using AI and biomarkers to develop personalized medications for mental disorders (such as depression). This chart shows bearish bets. Bears are skeptical that this approach will prove effective in clinical trials, given the complexity of treating mental illnesses.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alto-Neuroscience-Inc.-ANRO&v=1772681293116 "Short Shares Chart for the Company Alto Neuroscience Inc. (ANRO)")
Shares shorted by market segment - Pharma psycho
Alto Neuroscience is a biotech company using AI and biomarkers to develop personalized medications in psychiatry. This chart shows overall short positions in the biotech (psychiatry) sector. The high short position in this area reflects market skepticism about the complexity of treating mental disorders.
Shares shorted by the overall market
Alto Neuroscience (ANRO) is a clinical-stage biotech. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alto Neuroscience Inc. (ANRO)
Alto Neuroscience is using AI to develop "personalized" drugs for mental disorders. This is a groundbreaking, yet speculative, R&D bet. This chart measures the level of hype. It shows when the euphoria from trial data or AI hype (overbought) or doubts about the platform (oversold) peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alto-Neuroscience-Inc.-ANRO&v=1772681293256 "RSI 14 indicator chart for the company's stock Alto Neuroscience Inc. (ANRO)")
RSI 14 Market Segment - Pharma psycho
Alto Neuroscience (ANRO) is "precision" psychiatry. This biotech uses *AI* and *biomarkers* (EEG) to *select* the "right" *antidepressant* for each patient. The "Pharma psycho" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is ANRO's growth just their "AI niche" or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Alto Neuroscience (ANRO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ANRO (Alto Neuroscience Inc.)
Alto Neuroscience is a biotech company using AI and biomarkers to develop personalized treatments for depression and other mental disorders. This chart shows the average target price. Analysts' forecasts are based on the success of its precision psychiatry platform and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ANRO-Alto-Neuroscience-Inc.&v=1772681293365 "A chart showing analyst consensus forecasts for the expected stock price. ANRO (Alto Neuroscience Inc.)")
The difference between the consensus estimate and the actual stock price ANRO (Alto Neuroscience Inc.)
Alto Neuroscience is a company developing "precision psychiatry." Their goal is to use AI and biomarkers (EEG) to select the right medication for depression. This chart shows the analysts' forecast for the stock's upside or downside. It measures the gap between the price and the forecast, reflecting their faith in this breakthrough R&D approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ANRO-Alto-Neuroscience-Inc.&v=1772681293430 "A chart showing the difference between the consensus forecast and the actual stock price. ANRO (Alto Neuroscience Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Alto Neuroscience is a biotech company using AI and biomarkers to develop "precision psychiatry"—selecting the right medication for depression. This chart reflects general expectations for the psychopharma sector, demonstrating whether experts believe a breakthrough in "personalized" depression treatment is possible.
Analysts' consensus forecast for the overall market share price
Alto Neuroscience (ANRO) is a biopharmaceutical company trying to "hack" psychiatry. They use AI and biomarkers (EEG) to match the right depression drug to the right patient. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough R&D platforms in this highly complex field of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alto Neuroscience Inc.
Alto Neuroscience is an AI psychiatrist. It's a biotech company that uses AI and biomarkers (EEG, genetics) to predict which drugs will help which patients with depression or PTSD. This graph is a pure indicator of their R&D. It reflects their progress in patient matching and the market's confidence in their precision approach to brain treatment.
AKIMA Market Segment Index - Pharma psycho
Alto Neuroscience uses AI and biomarkers to develop personalized medications for mental disorders (such as depression), tailoring the drug to the patient. This chart shows the average pharma sector index, giving investors a benchmark for how Alto's high-tech approach compares to the sector average.
The AKIM Index for the overall market
Alto Neuroscience is a company using biomarkers (AI-based brain analysis) to develop personalized medications for depression and schizophrenia. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this "precision psychiatry" story fits in with the overall economic trends affecting biotech.
